- Home/In The News/Blog/2013/October
31
October2013
category:
503b CompoundingPharmagen Announces Shift In Growth Strategy
SILVER SPRING, Md., Oct. 31, 2013 Pharmagen, Inc. (OTCBB: PHRX) (the “Company” or “Pharmagen”) announces that it will shift its near-term focus to developing and deploying a business plan to build a solid foundation for revenue and EBITDA growth. Pharmagen’s multi-solution driven model and access to public markets are an attractive platform to build a significant […]
read more31
October2013
category:
503b CompoundingWSJ – FDA Sets New Rules to Better Address Drug Shortages
The Food and Drug Administration has forged plans to deal with the thorny medical issue of drug shortages, especially for sterile injectable drugs like those used in emergency medicine, cancer and intravenous nutrition. Under a new rule, the FDA will require companies to notify the agency of any plans to stop making drugs that are […]
read more31
October2013
category:
503b CompoundingMold in tainted medicine identified
Henry Ford Hospital identified Wednesday the types of mold it found in two vials of medicine supplied by a South Lyon compounding pharmacy. One of the vials was contaminated with penicillium, a fungus that rarely causes illness, and the other contained aspergillus, which has been known to cause illnesses, especially among those with weakened immune […]
read more